Biocon Yesafili: FDA approval, studies, 2026 US launch

Overview: what Biocon announced

Biocon Limited (BSE: 532523; NSE: BIOCON) said two clinical studies from its Phase III INSIGHT program for MYL-1701P, its aflibercept biosimilar, have been published in peer-reviewed journals. The company positioned the publications as adding to the clinical evidence supporting the development of aflibercept MYL-1701P for treating diabetic macular edema (DME). MYL-1701P is marketed as Yesafili (aflibercept-jbvf) in the United States.

The update sits alongside a broader sequence of regulatory approvals and settlement-backed commercialization timelines across the US, Canada, the UK, Europe, and other regions. Together, these events map out when and where Biocon Biologics expects to be able to launch Yesafili.

The Phase III INSIGHT evidence base

Biocon said clinical data from the Phase III INSIGHT program evaluating MYL-1701P has been published in two peer-reviewed journals. The company framed this as strengthening the overall evidence supporting the biosimilar’s development for DME.

While Biocon did not provide journal names or detailed efficacy endpoints in the provided text, it linked the publications to the broader case for aflibercept MYL-1701P as a biosimilar option in retinal disease. The announcement also connects the clinical program to the product’s regulatory status in key markets, where biosimilar and interchangeability decisions rely on a totality-of-evidence approach.

FDA status: Yesafili approved as interchangeable

Biocon said the US Food and Drug Administration approved Yesafili (aflibercept-jbvf) in May 2024. The text specifies May 20, 2024 as the first approval date.

Importantly, Biocon stated that the vial format received an interchangeable designation under the name Yesafili. Interchangeability in the US is a distinct regulatory designation that can allow substitution at the pharmacy level, subject to state laws and other requirements.

What Yesafili is used for

Yesafili is described as a vascular endothelial growth factor (VEGF) inhibitor and an interchangeable biosimilar to Eylea (aflibercept). In the US context provided, Yesafili is indicated for:

• Neovascular (wet) age-related macular degeneration (AMD)
• Macular edema following retinal vein occlusion (RVO)
• Diabetic macular edema (DME)
• Diabetic retinopathy (DR)

Biocon also referenced a broader set of ophthalmology uses in other jurisdictions, including myopic choroidal neovascularisation (myopic CNV) in materials related to the UK and certain other markets.

Product snapshot from disclosed details

The provided text includes specific product identifiers and dosage information for Yesafili.

The Health Canada section also states that treatment is for intravitreal injection only.

Settlements with Regeneron and Bayer: clearing commercialization pathways

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced settlement and license agreements designed to clear the path for commercialization in multiple regions. In the US, BBL announced on April 15, 2025 a settlement and license agreement with Regeneron that enables it to commercialize Yesafili in the United States.

The text also says the agreement includes dismissal of pending US legal proceedings, including an appeal at the US Court of Appeals for the Federal Circuit and litigation in the US District Court for the Northern District of West Virginia. Detailed settlement terms were described as confidential.

Separately, BBL also announced a settlement and license agreement with Regeneron and Bayer for biosimilar aflibercept (40 mg/ml) covering Europe and the rest of the world, following an earlier settlement covering the US and Canada. Biocon said this agreement clears the way to commercialize Yesafili in all countries worldwide.

Canada: Health Canada approval and July 2025 launch

BBL said Health Canada granted a Notice of Compliance (NOC) for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. The company stated this approval paves the way for a Canada launch scheduled for July 4, 2025.

BBL also described Yesafili as the first biosimilar to Eylea approved by Health Canada. In its US and Canada settlement context, Biocon additionally referenced an agreement in Canada with Bayer Inc. and Regeneron Pharmaceuticals, Inc., for launch no later than July 1, 2025.

UK and Europe: regulatory clearances and launch timing

Biocon said it received UK marketing authorization from the MHRA for YESAFILI on November 13, 2023. In addition, Biocon referenced successful approvals in Europe in September 2023 and in the United Kingdom in November 2023, stating it became the first biosimilar aflibercept approved in those markets.

On commercialization timing, Biocon stated that a settlement and license agreement enables launch in the United Kingdom in January 2026 and in the rest of the settled countries in March 2026, or earlier in certain circumstances.

United States: expected launch window in H2 2026

Although FDA approval occurred in May 2024, Biocon’s stated US launch timing is tied to settlement terms. The company said the Regeneron settlement enables launch in the second half of calendar year 2026, or earlier in certain circumstances.

The text also notes that Biocon Biologics secured a market entry for its biosimilar aflibercept for the US in April 2025, for the second half of calendar year 2026 or earlier in certain circumstances.

Key timeline and facts at a glance

The disclosures span regulatory approvals, settlements, and scheduled launches across regions.

Market context: what the developments signal

The sequence of approvals and settlement-driven launch windows shows how ophthalmology biosimilars can require both scientific evidence and legal clarity before meaningful commercialization. Biocon’s update links new Phase III INSIGHT publications with an already-established FDA approval and interchangeability designation, while settlements help define when sales can begin in major markets.

One market datapoint cited in the provided text came from InvestingPro: Biocon’s fair value was stated at INR 360.7 per share, implying a 10.5% upside from a current market price of INR 326.8. The company itself did not provide a valuation estimate in the supplied material.

Conclusion

Biocon’s latest update adds published Phase III INSIGHT clinical evidence to a regulatory and legal pathway that is already advanced in several regions for Yesafili, its aflibercept biosimilar to Eylea. With Health Canada clearance and a Canada launch scheduled for July 2025, followed by planned UK and broader launches in early 2026 and a targeted US launch window in H2 2026, the next milestones are largely calendar-driven based on stated settlement terms and regional rollout plans.